首页
登录
职称英语
Small, pink and very ugly. Hardly the qualities of a star, but they describe
Small, pink and very ugly. Hardly the qualities of a star, but they describe
游客
2025-05-08
1
管理
问题
Small, pink and very ugly. Hardly the qualities of a star, but they describe the deformed mouse that was the media darling at a recent science exhibition in Beijing. With a complex tissue structure in the shape of a human ear grafted on to its back, the rosy rodent was a stunning symbol of the serious strides China is making in the field of biotechnology.
China is fast applying the latest life-science techniques learned from the West m aggressively pursue genome research. It’s establishing its own centers of technical excellence to build a scientific base to compete directly with the United States and Europe. With a plentiful supply of smart young scientists at home and lots of interest abroad biotechnology is on the brink of a boom in China and in the view of foreign scientists, Beijing is playing a clever hand, maximizing the opportunities open to them.
For the moment, the cooperation exists mostly with Europe and the U. S. But Asia’s other biotech leaders, Japan, Singapore and Korea, also are recognizing China’s potential as an attractive low-cost base to conduct research. These partnerships--and China’s advancement in the field of biotechnology--could help benefit the rest of Asia: China’s rapid progress in improving crop yields will address food-security concerns in the region. In addition, China is more likely to focus on developing cheap technology that its predominantly poor population--and those of other Asian countries--can afford.
There remain, however, serious barriers to the development of a strong biotech industry. Among them are a poor domestic legal framework, weak enforcement of intellectual-property rights and loose adherence to international standards. China is a signatory of the International Bio Safety Protocol, which should mean adherence to global standards governing the conduct of field trims. But some observers are skeptical. "The regulations look good, but I haven’t met one scientist who believes they are being fully adhered to," says a European science analyst.
If shortcuts are taken, then some of the recent scientific achievements trumpeted in the official press may never make it to market. But no matter how strict lab tests are, other problems lie in wait. For example, there is a number of tasks it would take years to fulfill in the patents office, says one lawyer, leaving innovators with little protection if they take a product to market in China. [br] The phrase "on the brink of a boom" (in boldface in Paragraph 2) in the context means ______.
选项
A、having an edge in competition
B、in great demand
C、on the way to success
D、preparing for challenge
答案
C
解析
转载请注明原文地址:https://tihaiku.com/zcyy/4067306.html
相关试题推荐
Small,pinkandveryugly.Hardlythequalitiesofastar,buttheydescribe
Hardly______whenaloudexplosionwasheard.A、thetrainhadstartedB、thetrai
Tomcouldhardly______hisexcitementasheknewthathehadmadearealdiscov
OneworddescribeswhatmakesSingaporework:discipline.A、punishmentB、regulati
I______toonedailynewspaperandoneweeklymagazine.A、describeB、prescribeC
(It)wouldbe(hardly)forMrsSharptofind(a)man(ofparts)aroundher.A、It
Furthereducationisofficially(described)asthepost-secondarystageofeduca
AnaisNin’sdiariesareoftenscandalous,probablybecauseshedescribesherself
Hardlyanything______morethanhappinessofseeingsomeoneusinghisdevicefor
Therewas(hardlysomebody)intheroomwhopaid(any)attentiontohim(eventh
随机试题
[originaltext]M:I’mtalkingtoJanetHolmeswhohasspentmanyyearsnegotiati
BasicsaboutSpringBreakSafety1.TravelsafetyValiddriving【T1】______Aw
[originaltext]Man:Doyouknowthethingthat’salwaysstruckmeasoddabouto
Thegreatestrecentsocialchangeshavebeeninthelivesofwomen.Duringt
Forthispart,youareallowed30minutestowriteashortessayentitledMyVie
噪声所致听力损伤在听力曲线图常以哪一频率为中心出现下陷A.5000Hz B.4
目前,我国国债发行的招标方式包括()。 Ⅰ.承销包销方式 Ⅱ.荷兰式 Ⅲ
临床治疗虚衰病证时,为求阴阳相济,在补阴时适当配用补阳药,此为A.阴病治阳B.阳
常用来描述疾病的分布,探讨发病因素的指标是A.某病死亡率B.病死率C.发病率D.
对诊断尚未明确的急腹症患者,可以采取的措施是A:用吗啡止痛 B:用阿托品解痉
最新回复
(
0
)